Pague Menos reports a **96.3 million reais profit** in Q3 2026, driven by **4.429 billion reais in gross revenue** and a reduced debt ratio. Same-store sales growth slows to **5.6%**, reflecting a shift in performance dynamics. The company’s financial health improves despite moderating in-store sales momentum.
CADE’s investigative body proposes approving Pague Menos’ acquisition of the pharmacy chain **Extrafarma** under conditions. The recommendation requires a merger control agreement to maintain competition in Brazil’s pharmacy market. The case now moves to CADE’s Tribunal for final review.
Jun 2022Conselho Administrativo de Defesa EconômicaNews article
Pague Menos acquires Extrafarma, expanding its store count by one-third and positioning itself as Brazil’s second-largest drugstore chain. The deal, valued at R$700 million, consolidates Pague Menos’ market presence under Ultrapar’s holding. The transaction strengthens its competitive footprint in the Brazilian retail pharmacy sector.
Pague Menos acquires Extrafarma from Ultrapar in a $133 million deal. The transaction involves 700 million reais and expands Pague Menos’ presence in Brazil’s drugstore market. The agreement was disclosed in a securities filing.
May 2021M&A Critique | THE WHYS AND THE HOWSNews article
